Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06654765
Starting soon Observational

Growth and Development of Children With Inborn Errors of Metabolism in Assiut Governorate

NCT06654765 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-08
Last updated
2024-10-23

Condition(s) studied

Inborn Errors of Metabolism

Study summary

Assessment of growth and development of children with inborn errors of metabolism in Assiut Governorate

Eligibility

Sex
ALL
Min age
1 Month
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Under five years old children with confirmed diagnosis of IEM. * Attending the study settings. Exclusion Criteria: * Patients diagnosed since birth with dysmorphic features. * Patients diagnosed since birth with congenital anomalies. * Patients with other neurological deficits (e.g. cerebral palsy, convulsions, birth anoxia…..)

Primary outcome measure(s)

  • • To assess weight (in kilograms) of children with IEM in Assiut governorate. — 1 year
    The weight will be measured to the nearest 0.1Kg and the patients in light clothes and bare feet. The child weight will be measured and the measurements will be plotted on the Egyptian growth charts of girls and boys for different ages from birth to five years old in order to assess their growth.
  • • To assess height (in meters) of children with IEM in Assiut governorate. — 1 year
    If the child is less than 2 years old or is unable to stand recumbent length will be measured to the nearest 0.1 cm. If the child is aged 2 years or older and able to stand, standing height will be measured to the nearest 0.1 cm. The child height will be measured and the measurements will be plotted on the Egyptian growth charts of girls and boys for different ages from birth to five years old in order to assess their growth.
  • • To assess the body mass index for age (BMI for age in kg/m^2) of children with IEM in Assiut governorate. — 1 year
    Body mass index for age (BMI for age) will be calculated in kg/m\^2 and plotted on the Egyptian growth charts of girls and boys for different ages from birth to five years old in order to assess their growth.
  • To assess development of children with IEM in Assiut governorate using the arabic version of the third edition of the Ages and Stages Questionnaires. — 1 year
    The Arabic version of the third edition of the Ages \& Stages Questionnaires (ASQ-3) will be used to identify developmental growth in children from one month to five and a half years . it measures development in 5 key domains: communication, gross motor, fine motor, problem solving, and personal-social domain. Each response on the questionnaire will be converted to a numerical value (usually equal to 10, occasionally to 5, and not yet to 0) in order to determine the score, then each domain's overall score will be summed. ASQ-3 has three scoring zones and the higher the score the better the child development for each developmental area separately.
  • • To assess knowledge of the mother regarding the child metabolic disease and dietary recommendations using a questionnaire to be designed. — 1 year
    Knowledge regarding the child inborn metabolic diseases such as disease definition, symptoms necessitate immediate hospital admission, disease complications, dietary requirement and restrictions.
  • Assessment of mother's practice using a questionnaire to be designed. — 1 year
    Dietary practice, child care, vaccination and follow up.

Trial sites (1)

FacilityCityRegionStatus
• Genetic counselling center at Al Weladea neighbourhood in Assiut governorate. • Genetics Center at Al-Iman General Hospital in Assiut governorate. • Genetics clinic at Assiut University paediatrics' hospital. Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06654765 on ClinicalTrials.gov ↗ ← All trials in Egypt